HeartSciences Announces Results and Adjournment of Annual Shareholder Meeting

January 18, 2024 Southlake, TX, Jan. 18, 2024 (GLOBE NEWSWIRE) — Heart Test Laboratories, Inc. d/b/a HeartSciences (Nasdaq: HSCS; HSCSW) (“HeartSciences” or the “Company”), an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, announced today the results of the Company’s 2024 Annual Meeting of Shareholders (the […]

Press release: AI-Driven Study Redefines Right Heart Health Assessment With Novel Predictive Model

Press Release AI-Driven Study Redefines Right Heart Health Assessment With Novel Predictive Model Departure from traditional methods marks a significant advance in evaluating heart health, paving the way for more innovative tools and improved patient outcomes A deep learning-based ECG analysis tool is able to identify patients at high risk for poor right ventricular function. […]

HeartSciences Reminds Stockholders to Vote at the Upcoming Annual Shareholder Meeting

January 3, 2024 Southlake, TX, Jan. 03, 2024 (GLOBE NEWSWIRE) — Heart Test Laboratories, Inc. d/b/a HeartSciences (Nasdaq: HSCS; HSCSW) (“HeartSciences” or the “Company”), would like to remind its shareholders to vote ahead of its upcoming 2023 Annual Meeting of Stockholders (“Annual Meeting”) on Wednesday, January 17, 2024 at 9:00 a.m. Eastern (8:00 a.m. Central) Time. All […]

HeartSciences Reports Second Quarter Fiscal 2024 Financial Results

December 14, 2023 Southlake, TX, Dec. 14, 2023 (GLOBE NEWSWIRE) — Heart Test Laboratories, Inc. d/b/a HeartSciences (Nasdaq: HSCS; HSCSW) (“HeartSciences” or the “Company”), an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, today reported financial results for the second quarter fiscal 2024 ended October 31, […]

HeartSciences Receives FDA Confirmation for 510(k) Clearance Pathway

December 5, 2023 Southlake, TX, Dec. 05, 2023 (GLOBE NEWSWIRE) — Heart Test Laboratories, Inc. d/b/a HeartSciences (Nasdaq: HSCS; HSCSW) (“HeartSciences” or the “Company”), an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, today announced that it has received confirmation from the FDA to change the […]

HeartSciences Announces Closing of License Agreements with the Icahn School of Medicine at Mount Sinai to Develop and Commercialize AI Cardiovascular Algorithms

November 20, 2023 Southlake, TX, Nov. 20, 2023 (GLOBE NEWSWIRE) — Heart Test Laboratories, Inc. d/b/a HeartSciences (Nasdaq: HSCS; HSCSW) (“HeartSciences” or the “Company”), an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, today announced the closing of its license agreements with the Icahn School of […]

HeartSciences’ MyoVista® wavECGTM Selected for Heart Screening of Irish Garda National Police Officers

November 13, 2023 Southlake, Texas, Nov. 13, 2023 (GLOBE NEWSWIRE) — Heart Test Laboratories, Inc. d/b/a HeartSciences (Nasdaq: HSCS; HSCSW) (“HeartSciences” or the “Company”), an AI-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, today announced that its MyoVista® wavECGTM has been selected by Cardiact Ltd (“Cardiact”) to be used in […]

HeartSciences Issues Investor Update Highlighting Recent Key Achievements and Positive Developments

October 19, 2023 Entered into Transformative Agreements with Icahn Mount Sinai Filed FDA Pre-Submission Request to Change to 510(k) Submission from De Novo following Issuance of New Classification for AI ECG by FDA To host conference call on Wednesday, October 25, 2023 Southlake, TX, Oct. 19, 2023 (GLOBE NEWSWIRE) — Heart Test Laboratories, Inc. d/b/a HeartSciences (Nasdaq: […]

HeartSciences Receives Two New Patent Allowances, Expanding its International Patent Portfolio

September 26, 2023 Patents Cover MyoVista® Wavelet Technology Utilizing AI for Early Detection of Heart Disease Southlake, Texas, Sept. 26, 2023 (GLOBE NEWSWIRE) — Heart Test Laboratories, Inc. d/b/a HeartSciences (Nasdaq: HSCS; HSCSW) (“HeartSciences” or the “Company”), an AI-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, today announced […]